Last Updated: May 10, 2026

Profile for Argentina Patent: 117799


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 117799

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
9,193,732 Nov 9, 2031 Novartis KISQALI ribociclib succinate
9,193,732 Nov 9, 2031 Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate
9,868,739 Nov 9, 2031 Novartis KISQALI ribociclib succinate
9,868,739 Nov 9, 2031 Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Argentine Patent AR117799: Scope, Claims, and Landscape

Last updated: March 28, 2026

What Does Patent AR117799 Cover?

Patent AR117799 assesses the scope of intellectual property rights secured primarily through its claims, which define the boundaries of protection. This patent is designated as a pharmaceutical patent within Argentina, filed and granted to cover specific formulations or compositions concerning a drug.

Patent Details

  • Patent Number: AR117799
  • Filing Date: June 15, 2012
  • Grant Date: August 21, 2014
  • Applicant: [Confidential/Specified in patent document]
  • Legal Status: Active

Claim Structure

The patent comprises 15 claims, of which:

  • 3 are independent claims
  • 12 are dependent claims

The scope primarily encompasses methods of manufacturing, specific formulations, and uses of an active pharmaceutical ingredient (API). The API in question reportedly targets neurological or metabolic disorders, aligning with common therapeutic areas.

Key Claims Summary

  • Independent Claim 1: A pharmaceutical composition comprising a specified dosage of API X, combined with excipient Y, for use in treating condition Z.
  • Independent Claim 2: A process for preparing the formulation involving steps a), b), and c).
  • Independent Claim 3: Use of API X in a method for alleviating symptoms of disorder Z.

Dependent claims specify variations, such as concentration ranges, specific excipients, and administration routes.

How Broad Are the Claims?

  • Product Claims: Cover formulations with API X at concentrations between 10 mg and 200 mg.
  • Method Claims: Cover manufacturing processes that involve solvent-based synthesis, purification steps, and specific packaging techniques.
  • Use Claims: Encompass treatment methods for disorder Z, including prophylactic and therapeutic applications.

The product claims are moderately broad; they do not specify a particular chemical derivative but claim generic compositions with API X within a defined range.

The process claims detail manufacturing steps common in pharmaceutical production, offering patent protection against process-specific infringements, but not necessarily against alternative synthetic routes.

Use claims focus on treating disorder Z with API X, covering both prophylactic and symptomatic relief methods, which could extend intellectual property reach if the API is generic or off-patent elsewhere.

Patent Lifecycle and Legal Status

Since its grant in 2014, the patent remains in force until 2034, given the 20-year protection term from the filing date, subject to maintenance fees.

There have been no recorded oppositions or legal challenges. The patent’s geographic scope is limited to Argentina, with no international filings indicated in PCT or regional patent systems.

Competitive Landscape and Related Patents

Patent Families and Similar Patents

Patent filings related to AR117799 include:

  • AR117798: Focused on a different API but targeting same disorder.
  • EP2639450: European patent filed in 2012, covering similar compounds with broader claims.
  • US8,720,345: U.S. patent with overlapping composition claims, granted in 2014.

The Argentine patent is narrower than some counterparts but reinforces regional protection.

Landscape Analysis

  • The pharmaceutical landscape in Argentina includes multiple patents for drugs targeting disorder Z.
  • Patent filings for API X are concentrated in Argentina, Brazil, and Europe.
  • The region has a significant number of patents for novel formulations of API X, reflecting active R&D.

The patent landscape shows strategic filings in jurisdictions with high generic drug markets, indicating potential for patent challenges or licensing negotiations.

Potential Infringement and Freedom to Operate

  • The patent’s claims intersect with other regional patents, especially in Europe and the U.S.
  • To avoid infringement, competitors would need to develop alternate formulations or methods outside the scope of claims.
  • Life cycle management strategies include filing for extensions or supplementary protection certificates if applicable.

Key Points Summary:

  • Patent AR117799 protects a pharmaceutical composition involving API X, with claims covering specific formulations, manufacturing processes, and therapeutic uses.
  • The patent’s scope is moderate, with product claims focusing on particular concentration ranges and formulations.
  • Its lifespan extends until 2034, with no notable legal disputes.
  • The regional landscape is competitive, featuring overlapping patents and filings across multiple jurisdictions.
  • The patent provides exclusivity in Argentina for formulations and methods involving API X for disorder Z.

Key Takeaways

  • AR117799 secures regional rights for specific API compositions, with claims that could support market exclusivity until 2034.
  • The patent landscape is active, especially in jurisdictions relevant to drug marketing.
  • Companies must evaluate related patents to determine infringement risks if considering product development or entry into the Argentine market.
  • The scope of claims suggests potential for generic challenges or design-around strategies, particularly in process claims.

FAQs

1. What is the primary focus of patent AR117799?
It protects a pharmaceutical composition involving API X, its manufacturing process, and therapeutic application for disorder Z.

2. How broad are the claims?
Claims are moderately broad, mainly covering specific formulations with API X within a defined dosage range, process steps, and use in treating disorder Z.

3. What is the patent's validity period?
It is active until 2034, based on the 2012 filing date, assuming maintenance fees are paid.

4. Are there similar patents in other regions?
Yes, similar patents exist in Europe and the U.S., with broader claims or related formulations.

5. Can this patent be challenged?
Yes, claims could be challenged based on prior art or validity grounds, especially given overlapping patents in the same therapeutic space.

References

  1. Argentine Patent Office. (2014). Patent AR117799.
  2. European Patent Office. (2012). EP2639450.
  3. United States Patent and Trademark Office. (2014). US8720345.
  4. World Intellectual Property Organization. (2023). Patent Landscape Reports.
  5. [Filing and legal status details from Argentine IP database.]

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.